Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F11 | P03951 | 1/20 | 0.45 |
| ▸ | ENPP2 | Q13822 | 6/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.34 |
| ▸ | TTR | P02766 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2722490 | 0.84 | F11 (0.45) | F11ENPP2CA1CA2KDM4E | |
| SCHEMBL29650231 | 0.84 | F11 (0.45) | F11ENPP2CA1CA2KDM4E | |
| Hydrochloric Acid SCHEMBL17645949 | 0.82 | F11 (0.48) | F11ENPP2CA1CA2KDM4E | |
| SCHEMBL29951218 | 0.82 | ENPP2 (0.44) | F11ENPP2CA1CA2TTR | |
| SCHEMBL1019278 | 0.82 | ENPP2 (0.44) | F11ENPP2CA1CA2TTR | |
| SCHEMBL3082470 | 0.80 | LPL (0.47) | ENPP2CA1CA2 | |
| SCHEMBL18705814 | 0.77 | KDM4E (0.45) | ENPP2CA1CA2KDM4EALDH1A1 | |
| SCHEMBL22249682 | 0.76 | ENPP2 (0.34) | ENPP2CA1CA2KDM4ETTR | |
| Hydrochloric Acid SCHEMBL20768995 | 0.76 | KDM4E (0.44) | F11KDM4EALDH1A1TAAR1 | |
| SCHEMBL5688518 | 0.76 | ENPP2 (0.38) | ENPP2CA1CA2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190119281-A1 | Pyrazolopyrimidine Derivatives Useful as Inhibitors of Bruton's Tyrosine Kinase | LOXO ONCOLOGY INC (US) | 2019-04-25 | — | — | US | disclosed |
| EP-3154978-B1 | PYRAZOLOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF BRUTON'S TYROSINE KINASE | LOXO ONCOLOGY INC (US) | 2019-04-03 | — | — | EP | disclosed |
| CN-108419435-A | Compound and epigenetics for treating cancer | 新加坡科技研究局 | 2018-08-17 | — | — | CN | disclosed |
| US-9975897-B2 | Pyrazolopyrimidine derivatives useful as inhibitors of Bruton's tyrosine kinase | LOXO ONCOLOGY, INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-20170129897-A1 | Pyrazolopyrimidine Derivatives Useful as Inhibitors of Bruton's Tyrosine Kinase | LOXO ONCOLOGY, INC. | 2017-05-11 | — | — | US | disclosed |
| EP-3154978-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF BRUTON'S TYROSINE KINASE | Redx Pharma Plc (GB) | 2017-04-19 | — | — | EP | disclosed |
| WO-2015189620-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF BRUTON'S TYROSINE KINASE | REDX PHARMA PLC (GB) | 2015-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119281-A1 | Pyrazolopyrimidine Derivatives Useful as Inhibitors of Bruton's Tyrosine Kinase | BTK, SYK, LCK | F11 912/4885ENPP2 999/4885CA1 4709/4885 |
| US-20170129897-A1 | Pyrazolopyrimidine Derivatives Useful as Inhibitors of Bruton's Tyrosine Kinase | BTK, SYK, LCK | F11 912/4885ENPP2 999/4885CA1 4709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.